Copyright © 2021. Inderes Oyj. All rights reserved.

Physitrack

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
27.5.
2022

New initiatives to grow subscription sales in the pipelineSeasonality changes and adding new revenue streamShare trading at 15.5x EV/EBITDA for 2023eLower Virtual Care sales, but subscribers are set to growThe Q1 results came in slightly below our ex

Muut analyysit
25.5.
2022

Q1 sales of EUR 2.6m (-5.7% vs ABGSC)The number of subscribers +17% y-o-y (vs ABGSC 21%)Expect relatively small forecasts changesQ1 resultsSales EUR 2.6m (-5.7% vs ABGSC 2.7m and -8.0% vs cons 2.8m), EBITDA EUR 0.3m (-38.0% vs ABGSC 0.4m), Adj.

Muut analyysit
10.5.
2022

Physitrack stays strong despite external disruptions We add Champion Health to the figuresShare trades more than 40% below Nordic SaaS peersM&A agenda continues strongly – three acquisitions in H1 Since Physitrack is not exposed to external facto

Muut analyysit
9.5.
2022

Acquires a leading digital workplace health platformAdding (at least) 3.2% to sales in ’22ePays 7.3x EV/sales, based on run rate sales of EUR 0.4mChampion Health - a leading workplace health platform Physitrack has acquired Champion Health, a leading

Muut analyysit
7.3.
2022

SaaS platform with a range of solutions for physiotherapy Organic sales CAGR of 24% in ’20/’21-’24eShare price range: SEK 42-69, 11x-17x ’23e EV/EBITDARecurring revenues, strong growth and EBITDA marginPhysitrack provides a digital platform with a wi

Physitrack

ipo